HEADLINE ALTERATION
The headline for the Physiomics plc
announcement released on 15 October 2024 at 11:30am under RNS No
2609I should read IMC Presentation on Company Website.
The announcement text is unchanged and is
reproduced in full below.
15 October 2024
Physiomics plc
("Physiomics" or the "Company")
IMC Presentation on Company
Website
Physiomics plc (AIM: PYC), a leading
mathematical modelling, data science and biostatistics company
supporting the development of new therapeutics and personalised
medicine solutions, recently provided a brief update
in-line with its End of Year results via Investor Meet Company and has updated
its website with the presentation.
The presentation and Q&A
from the meeting are now available at the Company's
website:
https://www.physiomics.co.uk/portfolio-item/investor-presentation-full-year-results-and-company-update/
Enquiries:
Physiomics
plc
Dr Jim Millen, Non-Executive
Chairman
Dr Peter Sargent, Chief Executive
Officer
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines expertise
across Modelling & Simulation, Biostatistics, Data Science and
Bioinformatics, together with deep biology expertise, to help
biotech and pharma companies streamline their drug development
journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and
clinical studies. Through use of cutting-edge computational tools,
bespoke models and our proprietary Virtual Tumour technology, the
Physiomics team has informed the development of over 100 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
